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ABSTRACT 
Objective: The purpose of this study was an implementation of quality by design (QbD) for the formulation and characterization of econazole 
nitrate loaded flexisomal nanocarriers (EN-FS) to improve antifungal activity and to enhance skin permeability.  
Methods: Initially quality target product profile (QTTP) elements were identified and later critical quality attributes (CQA) elements were defined 
from QTPP elements. Particle size, entrapment efficiency and deformability index were defined as CQAs. Risk assessment was performed by using 
fishbone diagram and failure mode and effect analysis (FMEA). Design space was created by using fractional factorial design 25-2 as screening design 
and 32 full factorial design as optimization design to optimize two variables soya phosphatidylcholine concentration(X1) and sodium deoxycholate 
concentration (X2
Results: Optimized batch of EN-FS was 249.5±3.48 nm, with entrapment efficiency of 88.6±0.89 % and deformability index of 31.75±0.98. Zeta 
potential analysis showed value of-22.5 mV. Morphological analysis by TEM showed spherical shaped flexisomes, which confirmed the vesicular 
characteristics. The optimized batch of EN-FS was further made into hydrogels by using sepineo P600 as gelling agent. The % drug diffusion of EN-
FS hydrogels had shown 24.68%. With higher skin deposition and higher value of zone of inhibition in antifungal study as compared to plain EN 
hydrogel. CLSM studies indicated deep penetration of EN-FS in skin layers. Lastly control strategy for EN-FS were developed.  
).  
Conclusion: It was concluded that EN-FS showed high flexibility and enhanced antifungal activity therefore found to be a potential nanocarriers for 
drug deposition in skin layers without disturbing skin integrity. 
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INTRODUCTION 
Quality by design (QbD) ensures that ‘quality should be built into 
product rather than tested in product’ as stated by quality expert 
Joseph M. Juran [1]. According to ICH Q8 R2 guidelines QbD is 
defined as “A systematic approach to development that begins with 
predefined objectives and emphasizes product and process 
understanding and process control, based on sound science and 
quality risk management” [2]. QbD made up of three ICH guidelines 
i.e. ICH Q8, Q9 and Q10 namely pharmaceutical development, quality 
risk management and pharmaceutical quality systems respectively. 
QbD has mainly four important elements (i) To identify quality 
target product profile (QTPP) based on prior knowledge. (ii)To 
define critical quality attributes (CQA’s), critical material attributes 
(CMA’s) and critical process parameters (CPP’s). (iii)To perform risk 
assessment by various tools such as ishikawa diagram (fishbone 
diagram) and failure mode effect analysis (FMEA). (iv) To establish 
design space and to define the control strategy. Three important 
tools of the QbD are design of experiments (DoE), process analytical 
technology (PAT) and risk management [3-6].  
Flexisomes are self-aggregating, deformable, flexible, stress-
responsive lipidic vesicle, its preferred form is an ultra-deformable 
vesicle which possess an aqueous core surrounded by the complex 
lipid bilayer. It carries both hydrophilic and hydrophobic properties. 
Flexisomes are referred as first generation of the elastic vesicles 
which made up of phospholipids and edge activator, Mandlik et al. 
[7]. Phospholipids which are used in preparation are soya 
phosphatidylcholine, egg phosphatidylcholine, dipalmitoyl 
phosphatidylcholine, distearoyl phosphatidylcholine. Various edge 
activators used in preparation of flexisomes are sodium cholate, 
sodium deoxycholate, span 80, and tween 80 which are single-chain 
surfactant that destabilizes the lipid membrane thus produce high 
flexibility, this flexibility leads to better permeation through pores of 
skin membrane [8-10]. Flexisomes overcome the skin penetration 
difficulty by squeezing themselves along the intracellular sealing 
lipid because of high vesicular flexibility, which permits entry in 
deeper layers of skin due to the mechanical stress of surrounding in 
a self-adapting manner. They can deform up to 3 to 4 times of their 
own diameter, and regain its shape, Cevc et al., Patidar et al. [11, 12].  
Skin is the largest organ of the human body and fungal skin infections 
are affecting over 50 million people all over the world especially in 
developing and underdeveloped nations, Gungor et al. [13]. Various 
imidazole derivatives have been used to treat topical fungal infections 
such as fluconazole, ketoconazole, clotrimazole, voriconazole, 
oxiconazole nitrate and miconazole nitrate. Econazole nitrate (EN) (1-
[2-(4-chlorophenyl) methoxy]-2-(2, 4-dichlorophenyl) ethyl)-1H-
imidazole mononitrate is a broad-spectrum imidazole antifungal drug 
mainly used to treat skin infections such as candidiasis, Keshri et al. 
[14]. EN belongs to the BCS class (IV) so it has both rate-limited 
release and permeability. EN blocks the ergesterol synthesis thus it 
prevents leads to prevention of fungal cell multiplication. EN 
commercially available as 1% cream and 1% liposomal gel. Flexisomes 
have been designed to overcome the problem of release and 
permeability, Sharma et al. [15]. 
In this research work, EN loaded flexisomal nanocarriers (EN-FS) 
were prepared by thin-film hydration method to improve skin 
permeability and antifungal activity by implementing QbD approach.  
MATERIALS AND METHODS 
Materials  
Materials used in this experiment were of AR/lR grade. Phospholipid 
used for vesicle formation was Lipoid S75 containing 70% 
phosphatidylcholine i.e. soya phosphatidylcholine (SPC) was 
obtained from Lipoid GmbH (Ludwigshafen, Germany). EN was 
purchased from Yarrow chemicals (Mumbai, India). Sodium 
deoxycholate (SDC) was obtained from Loba Chemicals Pvt. Ltd. 
(Mumbai, India) which was used as edge activator. Chloroform 
obtained from Loba Chemicals Pvt. Ltd. (Mumbai, India), Methanol 
was obtained from Merck India Ltd. (Mumbai, India). Disodium 
hydrogen phosphate and Potassium dihydrogen phosphate were 
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obtained from Loba Chemicals Pvt. Ltd. (Mumbai, India) and Sepineo 
P600 as a gelling agent was obtained from Air Liquide (Mumbai, 
India). 
Methods 
Identification of quality target product profile (QTPP) elements 
QTTP is a prospective summary of the quality characteristics of a 
EN-FS that ideally will be achieved to ensure the desired quality, 
taking into account safety and efficacy by patient’s point of view of 
the EN-FS. Based on the clinical and pharmacokinetic characteristics, 
preformulation studies and extensive literature survey QTPP 
elements for EN-FS were identified [3, 16, 17]. 
Determination of critical quality attributes (CQA) 
A CQA is defined as ‘any physical, chemical, biological property or 
characteristic that should be within an appropriate limit, range, or 
distribution to ensure the desired product quality’. CQA are 
generally associated with the drug substance, excipients, 
intermediates (in-process materials) and drug product. Based on 
prior knowledge, sound science CQA were defined from QTPP 
elements [3, 18]. 
Assessment of risk (RA) 
Initial RA was performed by using two tools as Ishikawa diagram 
(fish bone diagram) and failure mode and effect analysis (FMEA). 
Fish-bone diagram was considered as primary tool to identify the 
potential risks factor of formulation and development of flexisomes 
which could affects desired CQA. Based on prior knowledge FMEA 
method were further applied in the initial risk analysis of the 
parameters of the flexisomes [19], Each variable was evaluated in 
terms of severity (S), detectability (D) and probability (P). Severity is 
the how severely will be the variable affects to the final product. 
Detectability defined that a failure mode can be detected. The final 
parameter probability is considered as the occurrence probability or 
the likelihood of a failure. For each risk, S, D, P scores in the range of 
1 to 3 (low to high risk) were given and multiplied (S x D x P) to 
produce a “Risk Priority Number” (RPN). The RPN threshold was set 
at 15; any process parameter with an RPN 15 or above was regarded 
as a potential critical factor which impact on CQAs and in product 
safety and efficacy, while factors with a lower RPN can be eliminated 
from further study already stated by Nasr et al. [5, 20].  
Establishment of design space (DS) 
Design space is the multidimensional combination and interaction of 
critical material attributes and process parameters that have been 
demonstrated to provide assurance of quality [19]. Design space was 
established by using design of experiment (DoE) tool. In DoE, 25-2 
fractional factorial design as a screening design and 32
Preparation of EN-FS 
 full factorial 
design as a main optimization design were implemented [22, 23]. 
The EN-FS were prepared by modified thin film hydration method 
by using rotary evaporator and probe sonication [24]. Lipoid S75 
(SPC) as vesicle forming lipid, Sodium deoxycholate (SDC) as edge 
activator and EN were added to a round bottom flask and all the 
contents were dissolved in organic solvents (Methanol: Chloroform, 
1:1). The resulting mixture was set for rotary evaporation (60 °C for 
1 h) to form a thin lipidic film. The deposited lipidic thin film was 
hydrated by gentle shaking with 10 ml phosphate buffer solution of 
pH 7.4. The resulting vesicles were set aside to swallow for 2 to 3 h 
at room temperature to get large multi lamellar vesicles [7, 25]. 
Further size reduction of vesicles was obtained by probe sonication. 
Fractional factorial design as screening design (25-2
Based on risk assessment results, identified critical parameters 
further screened by 2
) 
5-2fractional factorial design. Five critical 
parameters (CPP and CMA) each varied with two levels were SPC 
concentration, X1 (250-500 mg), SDC concentration. X2 (100-150 
mg), probe sonication time, X3(2-4 min), Speed of the rotary 
evaporator, X4 (160-220 rpm) and hydration medium pH, X5
3
(6.8-
7.4) selected which may affect CQAs. As per screening design 8 
batches of flexisomes were prepared and evaluated.  
2
After screening design 2 supercritical parameters were selected and 
their effect on CQAs were optimized by 3
 full factorial design as optimization design 
2factorial design. Two super 
critical parameters each varied with three levels were SPC 
concentration, X1 (250-500-750 mg) and SDC concentration, X2.(50-
100-150 mg) were varied at three levels as high [+1], medium [0] 
and low [-1]. The predefined CQA’s were particle size (Y1), 
entrapment efficiency (Y2) and deformability index (Y3
Evaluation of the prepared flexisomes 
). 
Particle size determination (PS): mean particle size of EN-FS was 
measured by differential light scattering (DLS) by using particle size 
analyzer (Horiba SZ100, Japan) instrument. Polydispersity index 
was also determined to measure uniformity of particle diameter and 
it shows size distribution of the flexisomes. 
Entrapment efficiency (EE): Entrapment efficiency was determined 
by conventional method of centrifugation. Flexisomes suspension 
was placed in centrifuge tube for 30 min at 15000 rpm. Supernatant 
was withdrawn and further diluted with suitable solvent i.e. 
phosphate buffer solution of pH 7.4. EE was calculated by the 
formula [25]. 
%Entrapment Efficiency = (Total Drug−Unentrapped drug)
Total Drug
× 100 
Deformability index (DI): the elasticity of flexisomal vesicles were 
measured by extrusion method by membrane filtration. 
Deformability index is the measure of how elastic is the vesicle. 
Flexisomes were extruded through filter membrane (pore size 
diameter 100 nm) using a stainless steel filter holder, by applying 2 
bar pressure. Flexisomes were extruded for 5 min and quantity of 
suspension were measured. Deformability index was measured by 
formula [26-28]. 






DI = Deformability Index  
rv
and J = suspension amount extruded in 5 min, 
 = Vesicles size, rp = pore diameter 
Statistical analysis and regression analysis  
Statistical analysis of the design was carried out by using licensed 
Design Expert V-8 software (Stat Ease Inc. MN, USA). The obtained 
data were fitted in the Design Expert Software to analyze different 
statistical parameters. The regression analysis was expressed using 
polynomial equation (3), ANOVA, response surface plot (3-D graphs) 
and contour plots (2-D graphs) [29, 30]. 
Y=ß0+ß1 X1+ß2 X2+ß3 X1X2+ß4 X12+ß5 X2
Selection of optimized batch 
2 
Optimum formulation was selected by the critical evaluation from 
desirability factors. The criteria for selection of optimum 
preparations were primarily based on the highest possible values of, 
deformability index (DI), drug entrapment efficiency (%) and 
optimum value in range of (200 to 300 nm) of particle size i.e. 3 to 4 
times more than that of skin pore size, so flexisomes can squeeze 
themselves up to 3 to 4 times and can penetrate through narrow 
skin pores [7]. 
Evaluation of optimized batch 
Zeta potential measurements (surface charge study): sample firstly 
diluted with double distilled water and measurements were done in 
dip cell by differential light scattering (DLS) using instrument 
(Horiba SZ-100). The stability of vesicular suspension is directly 
related to the magnitude of the surface charge. Zeta potential value 
indicated stability of dispersion. 
Surface morphology study by transmission electron microscope 
(TEM): surface morphology study of optimized batch of flexisomes 
was carried out by transmission electron microscope (Phillips CM 
200, Netherland). Morphological structure and size were analyzed 
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by TEM. Flexisomal sample before extrusion and after extrusion 
through filter membrane were both analyzed under TEM [31]. 
Preparation of flexisomal loaded sepineo gel 
Sepineo P600 (Acrylamide/Sodium Acryloyldimethyl Taurate 
Copolymer/Isohexadecane and Polysorbate 80) was used as gelling 
agent in concentration range of 3% and 5% w/w [32]. Sepineo P600 
was added in flexisomal suspension in concentration range of 3% 
and 5%. Methyl and propyl paraben was added as preservative. Gel 
of good consistency and of pH 6 to 7 was prepared. Gel was 
evaluated by various parameters such as appearance, spreadability, 
viscosity, drug content, gel pH [33]. 
Spreadability 
The spreadability was measured by placing 0.5 gm gel sample within 
a circle of 1 cm diameter marked on a glass plate over which a 
second glass plate was placed. A weight of 0.5 kg was put on the 
upper glass plate for 5 min. The increase in the diameter due to 
spreading of gel sample was noted [35, 37]. 
Viscosity 
The viscosity of flexisomal gel were carried out on Brook-field 
viscometer. The sample (50 gm) was placed in a beaker and allowed 
to equilibrate for 5 min. before measuring the dial reading using T-B 
spindle at 0.5, 1, 2.5, and 5 rpm. At each speed, dial reading on the 
viscometer was noted. Direct multiplication of the dial readings with 
factors given in the Brookfield viscometer catalogue gave the 
viscosity in centipoises [34-37]. 
Drug content 
Drug content was determined by taking 1 g of flexisomal gel 
(equivalent to 1% of the drug) in 10 ml volumetric flask. From this 
solution, 1 ml was withdrawn and volume adjusted to 10 ml with 
methanol. The absorbance was taken at a λmax 264 nm by UV-
Spectrophotometer [35-37]. 
Ex vivo drug diffusion studies 
The drug diffusion studies were carried out using Franz-type 
diffusion cell on skin of human cadaver. Skin had taken from the 
abdominal region. Franz diffusion cell having effective diffusion area 
of 2.6 cm2
The drug deposited in the human cadaver skin was determined by drug 
deposition studies after diffusion study diffusion cell the after a period of 
7 h and the skin was removed. Gel was wiped off from surface of skin. 
Skin cut into small pieces further homogenized and the drug present in 
the skin was extracted with 50 ml methanol by means of sonication, after 
24 h filtered through 0.45 mm membrane filter and then analyzed with 
help of UV-visible spectrophotometer at wavelength 264 nm in suitable 
dilutions [7, 36, 37]. 
 was used for ex vivo drug diffusion studies of EN-FSs gel 
and compared with plain EN gel. Donor compartment which consists 
of EN-FSs gel at maintained temperature of 37±0.5 °C and sink 
condition was maintained. At set intervals of 1 to 7 h, sample of the 
receiver medium was withdrawn at the predetermined time and 
replaced immediately with an equal volume of fresh buffer solution 
of pH 7.4. UV–Visible spectrophotometer was used to analyze 
samples. The amount of EN permeated through human cadaver skin 
was plotted vs time [34, 35]. 
Drug deposition studies on human cadaver skin 
Histopathological study 
Histopathological examination of skin sample after diffusion was carried 
out and compared with piece of fresh excised untreated skin sample as a 
control. The skin was kept in 10% formalin for period of 24 h and then 
transverse section had taken (4 mm width). Each section was 
dehydrated by using ethanol and then embedded in paraffin wax. 
Transverse section was stained with hematoxylin and eosin and then 
observed under microscope in sufficient resolution [36, 38]. 
Confocal laser scanning microscopy (CLSM) 
Depth and mechanism of skin permeation of rhodamine red–loaded 
flexisomes was investigated using CLSM study. Rhodamine–red 
loaded flexisomal suspension was prepared with rhodamine red, 
soya lecithin (SPC) and sodium deoxycholate (SDC). Rhodamine red 
loaded flexisomes were prepared by conventional rotary 
evaporation sonication method. The formulation (i.e., containing 
vesicles was applied nonocclusively to the abdominal section of 
human cadaver skin. The skin sample was sliced in sections of 10–15 
μm in thickness through the z-axis and examined with confocal laser 
scanning microscopy (NIKON A1R; Tokyo, Japan). Optical excitations 
were carried out with a 488-nm argon laser beam, and fluorescence 
emission was detected above 560 nm for rhodamine red [38, 40]. 
In vitro antifungal activity 
The antifungal activity was determined against Candida albicans 
(ATCC 2091) species by cup plate method. The diameter of zone of 
inhibition was measured as an antifungal efficacy of plain gel and 
econazole nitrate loaded flexisomal gel. A sterilized sabouraud 
dextrose agar media was poured into sterilized petri plates; all 
conditions were taking place in an aseptic area. Suspension of Candida 
albicans culture was spread uniformly on the solidified sabouraud 
dextrose agar. The cups were cut and formulations were filled in 
laminar airflow by sterilized syringe. Plates were covered with lids 
and further incubated at 32 °C for 40 h. The zones of inhibition were 
measured. Aseptic condition was maintained during study [38, 40]. 
RESULTS AND DISCUSSION 
Identification of QTPP  
Based on scientific prior knowledge, a thorough literature survey 
and preliminary studies QTPP elements for the EN-FS were 
identified and are shown in table 1. 
Determination of CQA 
Based on scientific prior knowledge and preliminary studies three 
CQA were defined from QTPP elements as particle size, entrapment 
efficiency and deformability index. CQA and their justification is 
shown in table 2. 
 
Table 1: QTPP elements for econazole nitrate loaded flexisomes 
QTPP elements Target Justification 
Formulation Flexisomes For better skin permeability 
Dosage form Gel For better skin permeability. 
Route of administration Topical Pharmaceutical equivalence requirement: Same route of administration 
Stability At least 24 mo shelf life at room temp. Equivalent to or better than marketed preparation shelf-life 
Drug product quality 
attributes 
Physical attributes Pharmaceutical equivalence requirement: Meeting the same compendial or 








Container closure system Suitable container closure system to 
achieved target shelf life 
Selected based on similarity to the marketed preparation packaging. No 
further special protection is needed due to the stability of drug substance. 
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Assessment of risk  
Initial risk assessment was done by using ishikawa diagram 
(fishbone diagram) several critical parameters were obtained by 
ishikawa diagram which may affects CQA’s so as formulation 
which was preformed according to ICH Q8 R2, to identify a CPP 
and CMA of CQAs that affects the quality of flexisomes shown in 
fig. 1 (a). According to 5M concept, we had systematically 
gathered up all the possible factors in fishbone diagram that 
could influence flexisomal product quality, on the basis of 
literature data, various previous study experiences and 
preformulation data. 
 
Table 2: CQA elements for econazole nitrate loaded flexisomes 
CQAs Target Justification 
Particle Size Should be minimum (In range of 
200 to 300 nm) Larger than 
diameter of skin pores 
Particle size will affect the penetration through the skin. So as the effectiveness of the 
formulation. If particle size is larger than skin pores then flexisomes can squeeze themselves 
up to 3 to 4 times of their own diameter and can pass through narrow skin pores  
Entrapment 
Efficiency 
Should be maximum It will affect Drug release from the formulation. If more amount of drug gets entrapped in 
vesicle more drug will be present at the site of action 
Deformability 
Index 
Should be maximum Deformability index will affect the flexibility and also penetration through skin pores. 
 
By RPN score of FMEA which was based on prior knowledge and 
preliminary study, each variable was scored on Severity, 
Detectability and Probability of risk by fishbone factors. Five high-
risk factors which affects CQA was studied by FMEA and the score of 
RPN was above 15 (RPN>15) which were identified as critical 
factors in manufacturing the flexisomes shown in fig. 1 (b). Five 
parameters selected were 1. SPC concentration, 2. SDC 
concentration, 3. Probe sonication time, 4. Hydration medium pH 
and 5. Speed of rotary evaporator (RPM) as critical parameter which 
can severely affect the flexisomes, by taking this 5 parameters, 
design space was created and further used in fractional factorial 
design as a screening design. 
 
 
Fig. 1: (a): Fish-bone diagram illustrating factors that may have an impact on particle size, entrapment efficiency and deformability index 
(CQAs). (b): Risk priority number (RPN) score after failure mode and effect analysis risk assessments any variable above the RPN 
threshold of 15 was consider as a potential risk factors 
 
Establishment of design space 
A design of experiments (DoE) is an experimental tool was used to 
establish design space. In screening design, a 25-2 fractional factorial 
design was implemented with 8 runs, whereas 32 full factorial design 
with 9 runs was used as main optimization design. 
Screening of factors by 25-2
The results obtained from 2
 as screening design 
5-2
So that for optimization study, other three factors were excluded, and 
further study continued with SPC concentration and SDC concentration. 
 fractional factorial design were, particle 
size was found in range from 185.3±2.01 nm to 290.22±3.20 nm and 
entrapment efficiency in range from 70.3±2.14% to 81.8±1.89%. as 
shown in table 3. From screening design, it was seen that SPC 
concentration and SDC concentration significantly affected results of 
particle size and entrapment efficiency, as the effect of various 
independent variables in screening design is shown in pare to charts 
by means of t value effect in fig. 2. From pare to chart it was 
determined that two independent variables i.e. 1. SPC concentration 
(lipid conc.) and 2. SDC concentration (edge activator concentration) 
dominantly impacts particle size and entrapment efficiency.  
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Table 3: Design matrix for fractional factorial design (25-2
Std 
) (Screening design) 






time  (X) 3








1 250 mg 100 mg 2 min 220rpm 7.4 185.3±2.01 73.3±3.45 
2 500 mg 100 mg 2 min 160rpm 6.8 230.1±1.52 77.4±2.51 
3 250 mg 150 mg 2 min 160rpm 7.4 198.8±1.56 70.8±3.50 
4 500 mg 150 mg 2 min 220rpm 6.8 258.3±3.01 74.6±1.56 
5 250 mg 100 mg 4 min 220rpm 6.8 182.5±1.4 70.3±2.14 
6 500 mg 100 mg 4 min 160rpm 7.4 231.4±2.10 81.8±1.89 
7 250 mg 150 mg 4 min 160rpm 6.8 192.2±1.35 74.3±3.01 
8 500 mg 150 mg 4 min 220rpm 7.4 290.2±3.20 79.2±2.87 
SPC: Soya phosphatidylcholine, SDC: Sodium deoxycholate, Data are presented as mean±SD (n=3) 
 
 
Fig. 2: Pareto charts showing the effects of independent variables on (a) Particle size and (b) Entrapment efficiency. Soya 
phosphatidylcholine (SPC), Sodium deoxycholate (SDC) 
 
Optimization by 32 
9 batches were prepared with two independent variables as 1. SPC 
concentration and 2. SDC concentration which was evaluated at 
three levels with response variables as particle size (PS), 
entrapment efficiency (EE) and deformability index (DI). Results for 
9 batches are shown in table 4. R1 shows smallest particle size 
175.4±4.62 where R9 shows highest particle size as 614.5±4.68 
showed that particle size increases with increase in SPC 
concentration. The polydispersity index of all batches was found in 
range of 0.1 to 0. 4. Batch R1 shows smallest EE where R5 shows 
highest EE. Deformability index is an important property of 
flexisomes which states flexibility of the flexisomes. DI was done by 
extrusion method using assembly of membrane filtration. DI of all 
batches were in range of 16.21±0.15 to 31.75±0.98. R1 batch shows 
minimum DI where R5 shows maximum. It was found that DI 
increases as the concentration of edge activator increases as it 
destabilizes lipid bilayer to make it more flexible. 
full factorial design 
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R 250 mg 1 50 mg 175.4±4.62 72.6±0.66 16.21±0.15 
R 500 mg 2 50 mg 187.7±3.65 86.4±1.21 16.92±0.38 
R 750 mg 3 50 mg 279.9±6.14 87.4±0.36 18.37±0.32 
R 250 mg 4 100 mg 237.3±5.13 74.3±0.28 29.25±1.20 
R 500 mg 5 100 mg 249.5±3.48 88.7±0.89 31.75±0.98 
R 750 mg 6 100 mg 350.9±5.24 79.4±1.53 29.59±0.36 
R 250 mg 7 150 mg 156.3±3.65 69.79±0.68 22.13±0.94 
R 500 mg 8 150 mg 301.2±2.13 80.6±0.91 23.42±0.16 
R 750 mg 9 150 mg 614.5±4.68 75.5±0.16 20.75±1.25 
SPC: Soya phosphatidylcholine, SDC: Sodium deoxycholate, Data are presented as mean±SD (n=3) 
 
Statistical analysis 
Statistical model analysis for particle size (Y1) 
2FI model was found to be an adequate model for the particle size, 
2FI equation is shown as 
Y1(PS)=283.63+112.72X1+71.50X2+88.42X1 X2 (1) 
From above polynomial, it was found that particle size increases 
with increase in SPC concentration (X1) concentration also particle 
size increases with increase in SDC concentration (X2). Also 
interaction of both factors results in increases in particle size up to 
certain concentrations. In which SPC concentration significantly 
affects the particle size as compared to SDC concentration. Analysis 
of variance (ANOVA) was performed. It was found that the p-value is 
0.0074 which is less than 0.05 which indicates model terms were 
significant. 
Graphical representation 
Response surface plot in fig. 3 (a) shows that particle size increases 
either increase in SPC concentration or SDC concentration also 
interaction of both factors results in an increase in particle size as 
mentioned in polynomial equation. Effects of different proportion of 
various independent variables is shown in contour plot fig. 3 (b).  
Regression model analysis for entrapment efficiency [EE](Y2) 
Quadratic model was found to be an adequate model for the 
entrapment efficiency; quadratic equation is shown as, 
Y2(EE)=86.62+4.27X1-3.42X2-2.27X1 X2-8.73X12-2.09X2 2 (2) 
The above polynomial equation shows that SPC concentration (X1) 
has positive signs so that entrapment efficiency increases with 
increase in SPC (Lipid) concentration. In above equation X2 has 
negative coefficient which shows an increase in concentration of 
SDC (Edge activator) results in decrease in entrapment efficiency, 
although entrapment efficiency increases with increase in 
concentration of SDC up to certain limit above which there is 
decrease in entrapment efficiency. Also interaction of both factors 
shows negative coefficient which indicates decrease in entrapment 
efficiency. From quadratic equation it was found that X1 significantly 
affects the entrapment efficiency. Analysis of variance (ANOVA) was 
performed. It was found that p-value was 0.0372 which was less 
than 0.05 which indicates model terms were significant [41]. 
Graphical representation 
Response surface plot and contour plot is shown in fig. 3(c) and fig. 
3(d) respectively. Response surface plot shows that on an increase 
of concentration of X1, entrapment efficiency significantly increases. 
X2 shows negative effect on entrapment efficiency. Interaction of 
both factors results in slightly increase in entrapment efficiency, 
further increase in concentration results in decrease in entrapment 
efficiency as shown in polynomial equation.  
Regression model analysis for Deformability index (DI) [Y 3
Quadratic model was found to be adequate model for the 
deformability index, the quadratic equation is shown as 
Y
] 
3(DI)=31.07+0.1866X1+2.46X2-0.8850X1 X2-1.31 X1 2-10.56X22 (3) 
Above polynomial equation shows that both X1 and X2 bears 
positive coefficients. It shows that the deformability index increases 
with increase in both lipid (SPC) and surfactant (SDC) concentration 
but deformability index significantly increases with increase in 
concentration of surfactant (X2). Also interaction of both factors 
shows negative coefficient which indicates decrease in deformability 
index, although up to critical concentration interaction of both 
factors favors the deformability index. Analysis of variance (ANOVA) 
was performed. It was found that p-value 0.0037 which is less than 
0.05 which indicates model terms were significant.  
Graphical representation 
Response surface plot and contour plot is shown in fig. 3(e) and fig. 
3(f) respectively. Response surface plot shows that on an increase in 
concentration of SDC (Edge activator) shows increase in 
deformability index as edge activator destabilize lipidic membrane 
and provides flexibility to vesicle. Increase in concentration of SPC 
shows slightly increase in deformability index but effect of SPC on 
deformability index is low as compared to SDC i.e. X2.  The 
interaction of factors results in slightly increase then further 
decrease in deformability index.  
Risk assessment was updated for formulation variables based on the 
results of the formulation development studies and an acceptable 
range for the high risk, formulation a variable has been established 
and was included in the control strategy. 
Selection of optimized batch 
R 5
Surface morphology study by TEM: Flexisomes appeared as 
spherical and oval shape confirming the flexibility and vesicular 
characteristics, as shown in fig. 5. Two images of flexisomes as 
before filtration through extrusion membrane and after filtration 
through extrusion membrane shows that even passing through 100 
nm diameter extrusion membrane flexisomes had maintained their 
spherical and oval shape confirming flexibility and vesicular 
characteristics. SDC (edge activator) plays important role that has a 
high radius of curvature that destabilize the lipid bilayers of vesicle, 
and increases vesicle flexibility. 
 batch was selected as optimized batch as it showed optimum 
particle size 249.5±3.48. Particle size required for flexisomes 
should be higher 3 to 4 times than that of skin pores, so they can 
squeeze themselves 3 to 4 times and can pass through narrow 
skin pores, optimum range selected for the particle size of 
flexisomes were (200 to 300 nm) [7]. R5 showed maximum 
entrapment efficiency as 88.6±0.89 and maximum deformability 
index as 31.75±0.98. 
Evaluation of optimized batches 
Zeta potential measurements (surface charge study): The zeta 
potential value of the optimized EN-FS (R5) was found to be (-22.5 
mV) which shows a high negative surface charge on FSs which leads 
to high stability for the prepared formulation as it inhibits 
aggregation of vesicles due to negative charge, as shown in fig. 4. 
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Fig. 3: (a): Response surface plot for particle size (Y1). (b): Contour plot for particle size (Y1). (c): Response surface plot for entrapment 
efficiency (Y2) (d): Contour plot for entrapment efficiency (Y2). (e): Response surface plot for deformability index (Y3). (f): Contour plot 




Fig. 4: Zeta potential of optimized batch (R5 batch) 
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Fig. 5: TEM of econazole nitrate loaded flexisomes (R5
 
Evaluation of EN loaded FS gel 
EN-FS gel prepared was evaluated primarily on several factors as 
viscosity, spreadability, pH of gel and drug content. Gel showed 
optimum values of spreadability and viscosity at 3% concentration 
of Sepineo P600. Spreadability is an important property in the 
patient's point of view as good spreadability increases patient 
compliance, Spreadability found in range of 4 to 6 gm/sec. which 
indicated good spreadability. Drug content was found in range of 
93.2±% to 95.7±% which were in acceptable range. pH of flexisomal 
gel was found in range of 6.4±to 6.8±which was close to 
physiological pH of the skin. The viscosity of flexisomal gel should be 
in optimum range. Viscosity found 13400 centipoises [42]. 
Ex vivo drug diffusion studies 
The ex vivo drug diffusion profiles of EN-FS hydrogel and plain EN 
hydrogel formulation are shown in fig. 6. The percent drug diffusion 
at the end of 7 h was calculated. EN-FS hydrogel formulation showed 
considerably less skin permeation (14.12±%) as compared to plain 
EN hydrogel formulation (24.78±%) at the end of 7 h. From the 
results of the permeation study found that the EN-FS hydrogel 
showed slow and controlled release rather than irregular release of 
plain EN hydrogel. Drug encapsulated in flexisomes reduces the 
variability and irregularity in drug release profile. Controlled drug 
diffusion was most effective in topical formulation as the more 
amount of drug will be available at site of action in epidermis and 
dermis layers, thus will avoid systemic adverse side effects and will 
release its content slowly and gradually over the period of time [43]. 
Drug deposition studies on human cadaver skin 
) first before filtration through extrusion membrane second after filtration through 
extrusion membrane 
EN-FS hydrogel showed higher drug retention in skin as compared 
to plain EN hydrogel, EN-FS showed skin retention of 78.36±% and 
plain EN gel showed 48.52±%. As the more drug deposited in skin, 
then fungal infection treated more effectively in deep layers for a 
longer period of time. EN-FS gel is more efficient than plain EN 
hydrogel. As showed in fig. 7. 
Histopathological studies on human cadaver skin 
To check safety and irritancy of the skin after application of the gel, 
histopaths of human cadaver skin was taken and studied. Cadaver 
skin without treatment is used as control and EN-FS hydrogel 
treated cadaver skin is used as standard after 12 h of gel application. 
Histopaths are shown in fig. 8. Histopathology studies showed that 
no change in skin structure which shows safety of the formulation; 
there is no significant difference found in pathobiology of skin. After 
12 h of application integrity of skin was maintained. 
 
 
Fig. 6: Ex-vivo drug diffusion study of EN loaded TFs hydrogel 
and plain EN hydrogel through human cadaver skin, data are 
presented as mean±SD (n=3) 
  
 
Fig. 7: Skin deposition of EN FS gel and plain EN gel, data are presented as mean±SD (n=3) 
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Fig. 8: Histopathological photographs of (a) Control skin (without treatment) (b) econazole nitrate loaded flexisomal sepineo gel treated 
skin 
 
Confocal laser scanning microscopy studies 
The confocal photomicrographs corresponding to various formulations 
as shown in fig. 9. applied onto the human cadaver skin show that the 
penetration from plain EN hydrogel was observed only to the uppermost 
layer of the skin (stratum corneum). In contrast, enhanced delivery of 
rhodamine red labelled EN-FS hydrogel in terms of depth and quantity 
was observed (i.e., as far as the fifth layer of epidermis, the stratum 
basale). It was found that Rhodamine red labelled EN-FS showed higher 
retention in the skin layer and deeper penetration, this is due to the 
flexibility of the flexisomes, they can deform and can penetrate through 
deeper skin layers. Thus can be used to effectively treat fungal infections 
occurred in deep layers of skin. 
In vitro antifungal activity study 
Developed EN-FS hydrogel formulation was found to be more 
effective in anti-fungal activity as compared to plain EN hydrogel as 
shown in fig. 10. The zone of inhibition EN-FS hydrogel against 
Candida albicans was 38 mm compared to 18 mm of plain econazole 
nitrate gel, indicating significantly higher efficacy of econazole 
nitrate loaded flexisomal sepineo gel formulation. it was found that 
the developed EN-FS hydrogel formulation was more effective than 
the plain EN hydrogel. 
Design space was successfully established by using the design of 
experiment (DoE) tool. Fractional factorial design was used as 
screening design (25-2). Total 8 batches were prepared by using five 
factors with two levels. Three factors were excluded and further 
study continued with 2 critical factors. Further full factorial design 
(32
  
) was used as optimization design by using 2 factors evaluated at 
3 levels. Total 9 batches were prepared by using full factorial design, 
amongst 9 batches R5 batch was selected as optimized batch as it 
has optimum particle size, maximum entrapment efficiency and 
maximum deformability index. 
 
Fig. 9: CLSM images of (a) Plain econazole nitrate gel (b) Econazole nitrate loaded flexisomal gel showing deep penetration and retention 
in skin layers 
 
 
Fig. 10: In vitro antifungal activity of (a) plain econazole nitrate gel (b) econazole nitrate loaded flexisomal gel 
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Table 5: Control strategy for econazole nitrate loaded flexisomal gel formulation 






Purpose of control 
 
Critical material attributes 
SPC conc. Lipid (Vesicle forming 
agent) 




To ensure all flexisome’s CQAs to meet consistently 




To ensure all flexisomes CQAs to meet consistently 
Critical process parameters 
Rotary 
evaporation 





To ensure complete evaporation of organic solvent and to 
get thin uniform of lipidic vesicle. 
Rotavap Temp. 45 °C to 60 °C 
Probe 
sonication 
Probe sonication time 2 min to 4 min Optimization range 
studied 
To get desired nanosized vesicles. 
 
Control strategy 
A control strategy may include input material controls, process 
controls, and monitoring, design spaces around individual or multiple 
unit operations, and/or final product specifications used to ensure 
consistent quality. Control strategy for EN-FS is shown in table 5. 
CONCLUSION 
In this research work, EN-FS were successfully prepared and evaluated 
by implementing QbD approach using the conventional rotary 
evaporation sonication method. All three CQAs as particle size, 
deformability index and % entrapment efficiency was highly dependent 
on the concentration of SPC and EA(SDC). Morphological study analyzed 
by TEM revealed the spherical size, shape of EN-FS. The optimized batch 
of flexisomes was further formulated into hydrogel. Skin permeation of 
EN-FS hydrogel was less but showed regular profile of drug rather than 
irregular profile of plain EN gel, drug deposition studies obtained 
revealed higher drug deposition in EN-FS than plain EN gel formulation 
so that more amount of drug will be available at site of action. 
Histological examination on cadaver skin indicated safety of EN-FS 
hydrogel integrity of the skin was maintained and there was no 
significant change in pathobiology of skin after application of 
formulation. In vitro antifungal studies indicated that the developed EN-
FS hydrogel formulation was more effective as compared to plain EN 
hydrogel. CLSM studies showed that EN-FS hydrogel showed good 
penetration properties as compared to plain EN hydrogel. From the 
above studies it was concluded that EN-FS shows high flexibility and 
enhanced antifungal activity and deeper penetration through skin layers 
thus they are found to be a potential carrier for drug deposition in skin 
layers without disturbing its integrity.  
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